Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
73
BBC Quote, Financials, Valuation and Earnings
Last price:
$39.57
Seasonality move
:
-4.68%
Day range:
$39.44 - $40.02
52-week range:
$13.42 - $40.82
Dividend yield:
1.66%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
12.8K
Avg. volume:
34.3K
1-year change:
62.98%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$39.55 | -- | -- | -- | $0.66 | 1.66% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$80.82 | -- | -- | -- | $0.00 | 0% | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
$18.20 | -- | -- | -- | $0.12 | 7.91% | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
$124.50 | -- | -- | -- | $0.41 | 0.36% | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
$92.24 | -- | -- | -- | $0.02 | 0.08% | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
$110.20 | -- | -- | -- | $0.12 | 0.26% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.354 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 0.446 | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | 0.254 | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | 0.938 | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | 0.957 | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | 0.719 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
Virtus LifeSci Biotech Clinical Trials ETF vs. Competitors
-
Which has Higher Returns BBC or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is BBC or BBP More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.975, which suggesting that the stock is 2.512% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.640, suggesting its less volatile than the S&P 500 by 36.038%.
-
Which is a Better Dividend Stock BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.66%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or BBP?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns BBC or PFFR?
InfraCap REIT Preferred ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat InfraCap REIT Preferred ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- -
What do Analysts Say About BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand InfraCap REIT Preferred ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than InfraCap REIT Preferred ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than InfraCap REIT Preferred ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 PFFRInfraCap REIT Preferred ETF0 0 0 -
Is BBC or PFFR More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.975, which suggesting that the stock is 2.512% less volatile than S&P 500. In comparison InfraCap REIT Preferred ETF has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.454%.
-
Which is a Better Dividend Stock BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.66%. InfraCap REIT Preferred ETF offers a yield of 7.91% to investors and pays a quarterly dividend of $0.12 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. InfraCap REIT Preferred ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or PFFR?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than InfraCap REIT Preferred ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than InfraCap REIT Preferred ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while InfraCap REIT Preferred ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for InfraCap REIT Preferred ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- --
-
Which has Higher Returns BBC or XBI?
State Street SPDR S&P Biotech ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat State Street SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About BBC or XBI?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than State Street SPDR S&P Biotech ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than State Street SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XBIState Street SPDR S&P Biotech ETF0 0 0 -
Is BBC or XBI More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.975, which suggesting that the stock is 2.512% less volatile than S&P 500. In comparison State Street SPDR S&P Biotech ETF has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.765%.
-
Which is a Better Dividend Stock BBC or XBI?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.66%. State Street SPDR S&P Biotech ETF offers a yield of 0.36% to investors and pays a quarterly dividend of $0.41 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. State Street SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XBI?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Biotech ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than State Street SPDR S&P Biotech ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while State Street SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for State Street SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- --
-
Which has Higher Returns BBC or XHE?
State Street SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat State Street SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than State Street SPDR S&P Health Care Equipment ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than State Street SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XHEState Street SPDR S&P Health Care Equipment ETF0 0 0 -
Is BBC or XHE More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.975, which suggesting that the stock is 2.512% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Equipment ETF has a beta of 1.113, suggesting its more volatile than the S&P 500 by 11.281%.
-
Which is a Better Dividend Stock BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.66%. State Street SPDR S&P Health Care Equipment ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.02 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Equipment ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than State Street SPDR S&P Health Care Equipment ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for State Street SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns BBC or XHS?
State Street SPDR S&P Health Care Services ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat State Street SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than State Street SPDR S&P Health Care Services ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than State Street SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XHSState Street SPDR S&P Health Care Services ETF0 0 0 -
Is BBC or XHS More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.975, which suggesting that the stock is 2.512% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Services ETF has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.381%.
-
Which is a Better Dividend Stock BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.66 per share corresponding to a yield of 1.66%. State Street SPDR S&P Health Care Services ETF offers a yield of 0.26% to investors and pays a quarterly dividend of $0.12 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Services ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than State Street SPDR S&P Health Care Services ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for State Street SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
